Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
European Child & Adolescent Psychiatry
Erschienen in: European Child & Adolescent Psychiatry 10/2021

08.05.2020 | Review

A systematic review of therapeutic ketamine use in children and adolescents with treatment-resistant mood disorders

verfasst von: Susan Kim, Brittany S. Rush, Timothy R. Rice

Erschienen in: European Child & Adolescent Psychiatry | Ausgabe 10/2021

Einloggen, um Zugang zu erhalten

Abstract

Suicide is the second leading cause of death in the United States among individuals aged 10–24, and severe youth depression is often refractory to the current standards of care. Many studies have demonstrated the efficacy of ketamine in reducing depressive symptoms in adults with treatment-resistant mood disorders, though few studies utilizing ketamine in youth populations exist. This systematic review examines the current state of evidence for ketamine use in children with treatment-resistant mood disorders. We conducted a search utilizing two electronic databases for English-language studies investigating the therapeutic effects and side effect profile of ketamine in youth ≤ 19 years of age with a diagnosis of a treatment-resistant mood disorder. Analysis included subjects with treatment-resistant depression with and without psychotic features and with bipolar disorder. Primary outcome measures included the following scales: Montgomery–Asberg Depression Rating Scale, Children’s Depression Rating Scale, Children’s Depression Rating Scale Revised, Child Bipolar Questionnaire, Overt Aggression Scale, Yale–Brown Obsessive–Compulsive Scale, and Scale for Suicidal Ideation. Four published studies were identified that investigated therapeutic ketamine use in youth for the primary purpose of treating a treatment-resistant psychiatric disorder. Three additional studies that did not meet eligibility criteria were identified and discussed. Ketamine was shown in youth to generally improve depressive symptoms, decrease acute suicidality, and reduce mood lability, though a number of subjects remained resistant to its treatment. These findings substantiate the need for further longitudinal studies investigating ketamine’s long-term safety, its efficacy, and abuse potential in the youth.
Literatur
1.
Ghandour RM, Sherman LJ, Vladutiu CJ, Ali MM, Lynch SE, Bitsko RH et al (2019) Prevalence and treatment of depression, anxiety, and conduct problems in US children. J Pediatr 206:256–267PubMedCrossRef
2.
National Institute of Mental Health (2019) Mental Health Information, Statistics, Major Depression
3.
Bertha EA, Balázs J (2013) Subthreshold depression in adolescence: a systematic review. Eur Child Adolesc Psychiatry [Internet] 22(10):589–603CrossRef
4.
Clark MS, Jansen KL, Cloy JA (2012) Treatment of childhood and adolescent depression. Am Fam Physician [Internet] 86(5):442–448
5.
Kennard B, Silva S, Vitiello B, Curry J, Kratochvil C, Simons A et al (2006) Remission and residual symptoms after short-term treatment in the Treatment of Adolescents with Depression Study (TADS). J Am Acad Child Adolesc Psychiatry 45:1404–1411PubMedCrossRef
6.
March JS (2004) Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: treatment for Adolescents with Depression Study (TADS) randomized controlled trial. J Am Med Assoc 292:807–820CrossRef
7.
Brent D, Emslie G, Clarke G, Wagner KD, Asarnow JR, Keller M et al (2008) Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial. JAMA J Am Med Assoc 299:901–913CrossRef
8.
Emslie GJ, Mayes T, Porta G, Vitiello B, Clarke G, Wagner KD et al (2010) Treatment of resistant depression in adolescents (TORDIA): week 24 outcomes. Am J Psychiatry [Internet] 167(7):782–791CrossRef
9.
Vitiello B, Emslie G, Clarke G, Wagner KD, Asarnow JR, Keller MB et al (2011) Long-term outcome of adolescent depression initially resistant to selective serotonin reuptake inhibitor treatment: a follow-up study of the TORDIA sample. J Clin Psychiatry 72:388–396PubMedPubMedCentralCrossRef
10.
Berlim MT, Turecki G (2007) Definition, assessment, and staging of treatment-resistant refractory major depression: a review of current concepts and methods. Can J Psychiatry. 52:46–54PubMedCrossRef
11.
Souery D, Amsterdam J, de Montigny C, Lecrubier Y, Montgomery S, Lipp O et al (1999) Treatment resistant depression: methodological overview and operational criteria. Eur Neuropsychopharmacol [Internet] 9(1–2):83–91CrossRef
12.
Berlim MT, Turecki G (2007) What is the meaning of treatment resistant/refractory major depression (TRD)? A systematic review of current randomized trials. Eur Neuropsychopharmacol [Internet] 17(11):696–707CrossRef
13.
Werremeyer A (2014) Treatment-resistant depression. Ment Health Clin [Internet] 4(5):211–211CrossRef
14.
Birmaher B, Brent D (2007) Practice parameter for the assessment and treatment of children and adolescents with depressive disorders. J Am Acad Child Adolesc Psychiatry [Internet] 46(11):1503–1526CrossRef
15.
Mann JJ (2005) The medical management of depression. N Engl J Med [Internet] 353(17):1819–1834CrossRef
16.
Iiunma K, Arakawa Y, Takagi A, Kurata K, Ogihara T (1977) A simplified radioimmunoassay for serum aldosterone–non-extraction method with 125I-labeled aldosterone (author’s transl). Nihon Naibunpi Gakkai Zasshi [Internet] 53(6):797–809
17.
Braconnier A, Le Coent R, Cohen D, DEROXADO Study Group (2003) Paroxetine versus clomipramine in adolescents with severe major depression: a double-blind, randomized, multicenter trial. J Am Acad Child Adolesc Psychiatry [Internet] 42(1):22–29CrossRef
18.
Maayan L, Correll CU (2011) Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol [Internet] 21(6):517–535CrossRef
19.
Ghaziuddin N, King CA, Naylor MW, Ghaziuddin M, Chaudhary N, Giordani B et al (1996) Electroconvulsive treatment in adolescents with pharmacotherapy-refractory depression. J Child Adolesc Psychopharmacol 6:259–271PubMedCrossRef
20.
Wachtel LE, Jaffe R, Kellner CH (2011) Electroconvulsive therapy for psychotropic-refractory bipolar affective disorder and severe self-injury and aggression in an 11-year-old autistic boy. Eur Child Adolesc Psychiatry [Internet] 20(3):147–152CrossRef
21.
Puffer CC, Wall CA, Huxsahl JE, Frye MA (2016) A 20 year practice review of electroconvulsive therapy for adolescents. J Child Adolesc Psychopharmacol 26:632–636PubMedCrossRef
22.
Walter G, McDonald A, Rey JM, Rosen A (2002) Medical student knowledge and attitudes regarding ECT prior to and after viewing ECT scenes from movies. J ECT 18:43–46PubMedCrossRef
23.
Taieb O, Flament M, Corcos M, Jeammet P, Basquin M, Mazet P et al (2001) Electroconvulsive therapy in adolescents with mood disorder: patients’ and parents’ attitudes. Psychiatry Res 104:183–190PubMedCrossRef
24.
Croarkin PE, Wall CA, McClintock SM, Kozel FA, Husain MM, Sampson SM (2010) The emerging role for repetitive transcranial magnetic stimulation in optimizing the treatment of adolescent depression. J ECT 26:323–329PubMedPubMedCentralCrossRef
25.
Bloch Y, Grisaru N, Harel EV, Beitler G, Faivel N, Ratzoni G et al (2008) Repetitive transcranial magnetic stimulation in the treatment of depression in adolescents: an open-label study. J ECT 24:156–159PubMedCrossRef
26.
MacMaster FP, Croarkin PE, Wilkes TC, McLellan Q, Langevin LM, Jaworska N et al (2019) Repetitive transcranial magnetic stimulation in youth with treatment resistant major depression. Front Psychiatry [Internet] 10:170CrossRef
27.
Saluja G, Iachan R, Scheidt PC, Overpeck MD, Sun W, Giedd JN (2004) Prevalence of and risk factors for depressive symptoms among young adolescents. Arch Pediatr Adolesc Med [Internet] 158(8):760–765CrossRef
28.
Birmaher B, Ryan ND, Williamson DE, Brent DA, Kaufman J, Dahl RE et al (1996) Childhood and adolescent depression: a review of the past 10 years. Part II. J Am Acad Child Adolesc Psychiatry 35:1427–1439PubMedCrossRef
29.
Birmaher B, Ryan ND, Williamson DE, Brent DA, Kaufman J (1996) Childhood and adolescent depression: a review of the past 10 years. Part II. J Am Acad Child Adolesc Psychiatry 35:1427–1439PubMedCrossRef
30.
Fergusson DM, Woodward LJ (2002) Mental health, educational, and social role outcomes of adolescents with depression. Arch Gen Psychiatry 59:225–231CrossRefPubMed
31.
Vitiello B, Silva SG, Rohde P, Kratochvil CJ, Kennard BD, Reinecke MA et al (2009) Suicidal events in the treatment for adolescents with depression study (TADS). J Clin Psychiatry 70:741–747PubMedPubMedCentralCrossRef
32.
Domino EF, Chodoff P, Corsenn G (1965) Pharmacologic effects of CI-581, a new dissociative anesthetic, in man. Clin Pharmacol Ther [Internet] 6:279–291CrossRef
33.
Reich DL, Silvay G (1989) Ketamine: an update on the first twenty-five years of clinical experience. Can J Anaesth [Internet] 36(2):186–197CrossRef
34.
35.
Sadove MS, Shulman M, Hatano S, Fevold N (1971) Analgesic effects of ketamine administered in subdissociative doses. Anesth Analg [Internet] 50(3):452–457
36.
Ihmsen H, Geisslinger G, Schüttler J (2001) Stereoselective pharmacokinetics of ketamine: R(−)-ketamine inhibits the elimination of S(+)-ketamine. Clin Pharmacol Ther [Internet] 70(5):431–438CrossRef
37.
Li L, Vlisides PE (2016) Ketamine: 50 years of modulating the mind. Front Hum Neurosci [Internet] 10:612
38.
Reier CE (1971) Ketamine—"dissociative agent" or hallucinogen? N Engl J Med [Internet] 284(14):791–792
39.
Jansen KL (2000) A review of the nonmedical use of ketamine: use, users and consequences. J Psychoactive Drugs [Internet] 32(4):419–433CrossRef
40.
Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS et al (2000) Antidepressant effects of ketamine in depressed patients. Biol Psychiatry [Internet] 47(4):351–354CrossRef
41.
Zarate CA, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA et al (2006) A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63:856–864CrossRefPubMed
42.
Aan Het Rot M, Zarate CA, Charney DS, Mathew SJ (2012) Ketamine for depression: where do we go from here? Biol Psychiatry [Internet] 72(7):537–547CrossRef
43.
Sanacora G, Frye MA, McDonald W, Mathew SJ, Turner MS, Schatzberg AF et al (2017) A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiatry [Internet] 74(4):399–405CrossRef
44.
Peltoniemi MA, Hagelberg NM, Olkkola KT, Saari TI (2016) Ketamine: a review of clinical pharmacokinetics and pharmacodynamics in anesthesia and pain therapy. Clin Pharmacokinet [Internet] 55(9):1059–1077CrossRef
45.
Muller J, Pentyala S, Dilger J, Pentyala S (2016) Ketamine enantiomers in the rapid and sustained antidepressant effects. Ther Adv Psychopharmacol [Internet] 6(3):185–192CrossRef
46.
Moaddel R, Abdrakhmanova G, Kozak J, Jozwiak K, Toll L, Jimenez L et al (2013) Sub-anesthetic concentrations of (R, S)-ketamine metabolites inhibit acetylcholine-evoked currents in α7 nicotinic acetylcholine receptors. Eur J Pharmacol [Internet] 698(1–3):228–234CrossRef
47.
Zeilhofer HU, Swandulla D, Geisslinger G, Brune K (1992) Differential effects of ketamine enantiomers on NMDA receptor currents in cultured neurons. Eur J Pharmacol [Internet] 213(1):155–158CrossRef
48.
Chang L, Zhang K, Pu Y, Qu Y, Wang S-M, Xiong Z et al (2019) Comparison of antidepressant and side effects in mice after intranasal administration of (R, S)-ketamine, (R)-ketamine, and (S)-ketamine. Pharmacol Biochem Behav [Internet] 181:53–59CrossRef
49.
Fukumoto K, Toki H, Iijima M, Hashihayata T, Yamaguchi J-I, Hashimoto K et al (2017) Antidepressant potential of (R)-ketamine in rodent models: comparison with (S)-ketamine. J Pharmacol Exp Ther [Internet] 361(1):9–16CrossRef
50.
Yang C, Shirayama Y, Zhang J, Ren Q, Yao W, Ma M et al (2015) R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects. Transl Psychiatry [Internet] 5:e632CrossRef
51.
Zhang J-C, Li S-X, Hashimoto K (2014) R (−)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine. Pharmacol Biochem Behav [Internet] 116:137–141CrossRef
52.
Persson J, Hasselström J, Maurset A, Oye I, Svensson JO, Almqvist O et al (2002) Pharmacokinetics and non-analgesic effects of S- and R-ketamines in healthy volunteers with normal and reduced metabolic capacity. Eur J Clin Pharmacol [Internet] 57(12):869–875CrossRef
53.
54.
Correia-Melo FS, Leal GC, Carvalho MS, Jesus-Nunes AP, Ferreira CBN, Vieira F et al (2018) Comparative study of esketamine and racemic ketamine in treatment-resistant depression: protocol for a non-inferiority clinical trial. Medicine (Baltimore) [Internet] 97(38):e12414CrossRef
55.
56.
57.
Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M et al (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev [Internet] 4:1CrossRef
58.
Veritas Health Innovation. Covidence systematic review software [Internet]. Veritas Health Innovation (cited 18 Jan 2020)
59.
Montgomery SA, Asberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry [Internet] 134:382–389CrossRef
60.
Poznanski EO, Cook SC, Carroll BJ (1979) A depression rating scale for children. Pediatrics [Internet] 64(4):442–450
61.
Poznanski EO, Mokros HB (1996) Children’s Depression Rating Scale, Revised (CDRS-R), Los Angeles
62.
Papolos D, Hennen J, Cockerham MS, Thode HC, Youngstrom EA (2006) The child bipolar questionnaire: a dimensional approach to screening for pediatric bipolar disorder. J Affect Disord [Internet] 95(1–3):149–158CrossRef
63.
Yudofsky SC, Silver JM, Jackson W, Endicott J, Williams D (1986) The overt aggression scale for the objective rating of verbal and physical aggression. Am J Psychiatry 143:35–39PubMedCrossRef
64.
Storch EA, Murphy TK, Adkins JW, Lewin AB, Geffken GR, Johns NB et al (2006) The children’s Yale–Brown obsessive–compulsive scale: psychometric properties of child- and parent-report formats. J Anxiety Disord [Internet] 20(8):1055–1070CrossRef
65.
Beck AT, Kovacs M, Weissman A (1979) Assessment of suicidal intention: the Scale for Suicide Ideation. J Consult Clin Psychol [Internet] 47(2):343–352CrossRef
66.
Bremner JD, Krystal JH, Putnam FW, Southwick SM, Marmar C, Charney DS et al (1998) Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS). J Trauma Stress [Internet] 11(1):125–136CrossRef
67.
Cullen KR, Amatya P, Roback MG, Albott CS, Westlund Schreiner M, Ren Y et al (2018) Intravenous ketamine for adolescents with treatment-resistant depression: an open-label study. J Child Adolesc Psychopharmacol [Internet] 28(7):437–444CrossRef
68.
Papolos DF, Teicher MH, Faedda GL, Murphy P, Mattis S (2013) Clinical experience using intranasal ketamine in the treatment of pediatric bipolar disorder/fear of harm phenotype. J Affect Disord [Internet] 147(1–3):431–436CrossRef
69.
Zarrinnegar P, Kothari J, Cheng K (2019) Successful use of ketamine for the treatment of psychotic depression in a teenager. J Child Adolesc Psychopharmacol [Internet] 29:472–473CrossRef
70.
Dwyer JB, Beyer C, Wilkinson ST, Ostroff RB, Qayyum Z, Bloch MH (2017) Ketamine as a treatment for adolescent depression: a case report. J Am Acad Child Adolesc Psychiatry [Internet] 56(4):352–354CrossRef
71.
Castellanos A, Moleiro F, Guerrero J, Awaad MI, Myerburg RJ (1997) Intermittent parasystole with exit block. J Electrocardiol [Internet] 30(4):331–335CrossRef
72.
73.
Papolos D, Frei M, Rossignol D, Mattis S, Hernandez-Garcia LC, Teicher MH (2018) Clinical experience using intranasal ketamine in the longitudinal treatment of juvenile bipolar disorder with fear of harm phenotype. J Affect Disord [Internet] 225:545–551CrossRef
74.
American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders, 5th edn. Revision 4th edition with text, editor. American Psychiatric Press, Washington, DC, pp 1–2
75.
Beck AT (1988) Beck Hopelessness Scale, San Antonio
76.
Weber G, Yao J, Binns S, Namkoong S (2018) Case report of subanesthetic intravenous ketamine infusion for the treatment of neuropathic pain and depression with suicidal features in a pediatric patient. Case Rep Anesthesiol [Internet] 2018:9375910
77.
Guy W (1976) ECDEU Assessment Manual for Psychopharmacology. U.S. Government Printing Office, Rockville
78.
Mason KP, Padua H, Fontaine PJ, Zurakowski D (2009) Radiologist-supervised ketamine sedation for solid organ biopsies in children and adolescents. AJR Am J Roentgenol [Internet] 192(5):1261–1265CrossRef
79.
Sheehy KA, Muller EA, Lippold C, Nouraie M, Finkel JC, Quezado ZMN (2015) Subanesthetic ketamine infusions for the treatment of children and adolescents with chronic pain: a longitudinal study. BMC Pediatr [Internet] 15:198CrossRef
80.
Minoshima R, Kosugi S, Nishimura D, Ihara N, Seki H, Yamada T et al (2015) Intra- and postoperative low-dose ketamine for adolescent idiopathic scoliosis surgery: a randomized controlled trial. Acta Anaesthesiol Scand [Internet] 59(10):1260–1268CrossRef
81.
Zempsky WT, Loiselle KA, Corsi JM, Hagstrom JN (2010) Use of low-dose ketamine infusion for pediatric patients with sickle cell disease-related pain: a case series. Clin J Pain [Internet] 26(2):163–167CrossRef
82.
Finkel JC, Pestieau SR, Quezado ZMN (2007) Ketamine as an adjuvant for treatment of cancer pain in children and adolescents. J Pain [Internet] 8(6):515–521CrossRef
83.
Allen JY, Macias CG (2005) The efficacy of ketamine in pediatric emergency department patients who present with acute severe asthma. Ann Emerg Med [Internet] 46(1):43–50CrossRef
84.
Dobbing J, Sands J (1973) Quantitative growth and development of human brain. Arch Dis Child [Internet] 48(10):757–767CrossRef
85.
Dobbing J, Sands J (1979) Comparative aspects of the brain growth spurt. Early Hum Dev [Internet] 3(1):79–83CrossRef
86.
Hayashi H, Dikkes P, Soriano SG (2002) Repeated administration of ketamine may lead to neuronal degeneration in the developing rat brain. Paediatr Anaesth [Internet] 12(9):770–774CrossRef
87.
Ikonomidou C, Bittigau P, Koch C, Genz K, Hoerster F, Felderhoff-Mueser U et al (2001) Neurotransmitters and apoptosis in the developing brain. Biochem Pharmacol [Internet] 62(4):401–405CrossRef
88.
Liu F, Paule MG, Ali S, Wang C (2011) Ketamine-induced neurotoxicity and changes in gene expression in the developing rat brain. Curr Neuropharmacol [Internet] 9(1):256–261CrossRef
89.
Liu W, Ge T, Leng Y, Pan Z, Fan J, Yang W et al (2017) The role of neural plasticity in depression: from hippocampus to prefrontal cortex. Neural Plast [Internet] 2017:6871089
90.
Wang J, Zhou M, Wang X, Yang X, Wang M, Zhang C et al (2014) Impact of ketamine on learning and memory function, neuronal apoptosis and its potential association with miR-214 and PTEN in adolescent rats. PLoS One [Internet] 9(6):e99855CrossRef
91.
Yan J, Jiang H (2014) Dual effects of ketamine: neurotoxicity versus neuroprotection in anesthesia for the developing brain. J Neurosurg Anesthesiol [Internet] 26(2):155–160CrossRef
92.
Bates MLS, Trujillo KA (2019) Long-lasting effects of repeated ketamine administration in adult and adolescent rats. Behav Brain Res [Internet] 369:111928CrossRef
93.
Onaolapo AY, Ayeni OJ, Ogundeji MO, Ajao A, Onaolapo OJ, Owolabi AR (2019) Subchronic ketamine alters behaviour, metabolic indices and brain morphology in adolescent rats: involvement of oxidative stress, glutamate toxicity and caspase-3-mediated apoptosis. J Chem Neuroanat [Internet] 96:22–33CrossRef
94.
Hijazi Y, Boulieu R (2002) Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes. Drug Metab Dispos [Internet] 30(7):853–858CrossRef
95.
Martignoni M, Groothuis GMM, de Kanter R (2006) Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol [Internet] 2(6):875–894CrossRef
96.
Parise EM, Alcantara LF, Warren BL, Wright KN, Hadad R, Sial OK et al (2013) Repeated ketamine exposure induces an enduring resilient phenotype in adolescent and adult rats. Biol Psychiatry [Internet] 74(10):750–759CrossRef
97.
Lee K-H, Yeh Y-C, Yang P-C, Lin H-C, Wang P-W, Liu T-L et al (2012) Individual and peer factors associated with ketamine use among adolescents in Taiwan. Eur Child Adolesc Psychiatry [Internet] 21(10):553–558CrossRef
98.
Shepard RD, Langlois LD, Browne CA, Berenji A, Lucki I, Nugent FS (2018) Ketamine reverses lateral habenula neuronal dysfunction and behavioral immobility in the forced swim test following maternal deprivation in late adolescent rats. Front Synaptic Neurosci [Internet] 10:39CrossRef
99.
Naughton M, Clarke G, O’Leary OF, Cryan JF, Dinan TG (2014) A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action. J Affect Disord [Internet] 156:24–35CrossRef
100.
Abdallah CG, Adams TG, Kelmendi B, Esterlis I, Sanacora G, Krystal JH (2016) Ketamine’s mechanism of action: a path to rapid-acting antidepressants. Depress Anxiety [Internet] 33(8):689–697CrossRef
101.
Kraus C, Wasserman D, Henter ID, Acevedo-Diaz E, Kadriu B, Zarate CA (2019) The influence of ketamine on drug discovery in depression. Drug Discov Today [Internet] 24(10):2033–2043CrossRef
102.
Croarkin PE, Nakonezny PA, Husain MM, Melton T, Buyukdura JS, Kennard BD et al (2013) Evidence for increased glutamatergic cortical facilitation in children and adolescents with major depressive disorder. JAMA Psychiatry [Internet] 70(3):291–299CrossRef
103.
Haile CN, Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Foulkes A et al (2014) Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression. Int J Neuropsychopharmacol [Internet] 17(2):331–336CrossRef
104.
Pandey GN, Ren X, Rizavi HS, Conley RR, Roberts RC, Dwivedi Y (2008) Brain-derived neurotrophic factor and tyrosine kinase B receptor signalling in post-mortem brain of teenage suicide victims. Int J Neuropsychopharmacol [Internet] 11(8):1047–1061CrossRef
105.
Pandey GN, Dwivedi Y, Rizavi HS, Ren X, Zhang H, Pavuluri MN (2010) Brain-derived neurotrophic factor gene and protein expression in pediatric and adult depressed subjects. Prog Neuropsychopharmacol Biol Psychiatry [Internet] 34(4):645–651CrossRef
106.
Pandey GN, Rizavi HS, Dwivedi Y, Pavuluri MN (2008) Brain-derived neurotrophic factor gene expression in pediatric bipolar disorder: effects of treatment and clinical response. J Am Acad Child Adolesc Psychiatry [Internet] 47(9):1077–1085CrossRef
107.
Pacheco D da F, Romero TRL, Duarte IDG (2014) Central antinociception induced by ketamine is mediated by endogenous opioids and μ- and δ-opioid receptors. Brain Res [Internet] 1562:69–75CrossRef
108.
Williams NR, Heifets BD, Blasey C, Sudheimer K, Pannu J, Pankow H et al (2018) Attenuation of antidepressant effects of ketamine by opioid receptor antagonism. Am J Psychiatry [Internet] 175(12):1205–1215CrossRef
109.
Price RB, Iosifescu DV, Murrough JW, Chang LC, Al Jurdi RK, Iqbal SZ et al (2014) Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression. Depress Anxiety [Internet] 31(4):335–343CrossRef
110.
Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Green CE, Perez AM et al (2013) Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry [Internet] 170(10):1134–1142CrossRef
111.
Caddy C, Amit BH, McCloud TL, Rendell JM, Furukawa TA, McShane R et al (2015) Ketamine and other glutamate receptor modulators for depression in adults. Cochrane Database Syst Rev [Internet] 9:CD011612
112.
Coyle CM, Laws KR (2015) The use of ketamine as an antidepressant: a systematic review and meta-analysis. Hum Psychopharmacol [Internet] 30(3):152–163CrossRef
113.
Short B, Fong J, Galvez V, Shelker W, Loo CK (2018) Side-effects associated with ketamine use in depression: a systematic review. Lancet Psychiatry [Internet] 5(1):65–78CrossRef
114.
Feder A, Parides MK, Murrough JW, Perez AM, Morgan JE, Saxena S et al (2014) Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. JAMA Psychiatry [Internet] 71(6):681–688CrossRef
115.
Mathew SJ, Wilkinson ST, Altinay M, Asghar-Ali A, Chang LC, Collins KA et al (2019) Electroconvulsive therapy (ECT) vs. ketamine in patients with treatment-resistant depression: the ELEKT-D study protocol. Contemp Clin Trials [Internet] 77:19–26CrossRef
116.
AACAP Psychopharmacology Committee (2018) AACAP Psychopharmacology Committee Statement on Ketamine
117.
Turner EH (2019) Esketamine for treatment-resistant depression: seven concerns about efficacy and FDA approval. Lancet Psychiatry [Internet] 6(12):977–979CrossRef
118.
Singh JB, Daly EJ, Mathews M, Fedgchin M, Popova V, Hough D et al (2020) Approval of esketamine for treatment-resistant depression. Lancet Psychiatry [Internet] 7(3):232–235CrossRef
Metadaten
Titel
A systematic review of therapeutic ketamine use in children and adolescents with treatment-resistant mood disorders
verfasst von
Susan Kim
Brittany S. Rush
Timothy R. Rice
Publikationsdatum
08.05.2020
Verlag
Springer Berlin Heidelberg
Erschienen in
European Child & Adolescent Psychiatry / Ausgabe 10/2021
Print ISSN: 1018-8827
Elektronische ISSN: 1435-165X
DOI
https://doi.org/10.1007/s00787-020-01542-3

Weitere Artikel der Ausgabe 10/2021

European Child & Adolescent Psychiatry 10/2021 Zur Ausgabe

Original Contribution

The mental health effects of pet death during childhood: is it better to have loved and lost than never to have loved at all?

Original Contribution

Early regulatory problems and parenting: life-long risk, vulnerability or susceptibility for attention, internalizing and externalizing outcomes?

Original Contribution

Do cognitive interventions for preschoolers improve executive functions and reduce ADHD and externalizing symptoms? A meta-analysis of randomized controlled trials

Original Contribution

Adolescents’ somatic complaints in eight countries: what influence do parental rearing styles have?

Original Contribution

Get secure soon: attachment in abused adolescents and young adults before and after trauma-focused cognitive processing therapy

Original Contribution

Prenatal maternal infections and children’s socioemotional development: findings from the UK Millennium Cohort Study

Neu im Fachgebiet Psychiatrie

23.04.2024 | Demenz | Nachrichten

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 | Depression antepartal oder postpartal | Nachrichten

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

22.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

22.04.2024 | DGIM 2024 | Nachrichten

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein
weitere anzeigen

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen